We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+5.62%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.2B
AUM Growth
+$36.4M
Cap. Flow
+$49.6M
Cap. Flow %
2.25%
Top 10 Hldgs %
26.49%
Holding
159
New
12
Increased
46
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$23.1M
2
SYK icon
Stryker
SYK
+$19.3M
3
HOLX
Hologic
HOLX
+$13.4M
4
ZBH icon
Zimmer Biomet
ZBH
+$11.4M
5
MOH icon
Molina Healthcare
MOH
+$10.4M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$27.5M
2
DHR icon
Danaher
DHR
+$19.3M
3
MDT icon
Medtronic
MDT
+$19.2M
4
BCR
CR Bard Inc.
BCR
+$18.4M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.16%
2 Financials 2.8%
3 Consumer Discretionary 0.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$382B
$107M 4.87%
487,000
+28,000
+6% +$5.93M
AAAP
2
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$67.4M 3.06%
825,500
+41,000
+5% +$3.18M
CI icon
3
Cigna
CI
$78.4B
$65.2M 2.96%
321,000
+51,000
+19% +$10.2M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$57.4M 2.6%
480,000
+17,000
+4% +$2.07M
ISRG icon
5
Intuitive Surgical
ISRG
$127B
$52.5M 2.38%
431,700
-300
-0.1% -$37.5K
PCRX icon
6
Pacira BioSciences
PCRX
$1.04B
$50.5M 2.29%
1,106,700
+18,700
+2% +$741K
MRK icon
7
Merck
MRK
$322B
$47.9M 2.17%
891,534
+97,150
+12% +$5.39M
GWPH
8
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$46.7M 2.12%
354,000
-19,000
-5% -$2.23M
TSRO
9
DELISTED
TESARO, Inc.
TSRO
$45.5M 2.06%
548,500
+53,250
+11% +$5.22M
PRAH
10
DELISTED
PRA Health Sciences, Inc.
PRAH
$43.5M 1.97%
477,500
– –
MOH icon
11
Molina Healthcare
MOH
$10.4B
$43.5M 1.97%
567,000
+144,500
+34% +$10.4M
AET
12
DELISTED
Aetna Inc
AET
$43.1M 1.96%
239,000
-160,000
-40% -$27.5M
ACHC icon
13
Acadia Healthcare
ACHC
$2.52B
$40.9M 1.86%
1,253,500
-51,500
-4% -$1.78M
NBIX icon
14
Neurocrine Biosciences
NBIX
$18.2B
$37.7M 1.71%
486,000
+46,000
+10% +$3.14M
PBYI icon
15
Puma Biotechnology
PBYI
$398M
$36.9M 1.68%
373,500
+43,500
+13% +$4.87M
COLL icon
16
Collegium Pharmaceutical
COLL
$1.18B
$34.8M 1.58%
1,885,729
+80,729
+4% +$1.16M
ONCE
17
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$31.6M 1.43%
615,000
+18,000
+3% +$1.29M
CELG
18
DELISTED
Celgene Corp
CELG
$31.6M 1.43%
303,000
+40,500
+15% +$4.57M
MDGL icon
19
Madrigal Pharmaceuticals
MDGL
$12.6B
$31.4M 1.42%
342,000
+67,000
+24% +$3.83M
RDUS
20
DELISTED
Radius Health, Inc.
RDUS
$30M 1.36%
943,000
– –
PEN icon
21
Penumbra
PEN
$12.6B
$29.2M 1.33%
310,500
– –
JNJ icon
22
Johnson & Johnson
JNJ
$640B
$27.9M 1.27%
200,000
+25,000
+14% +$3.48M
WCG
23
DELISTED
Wellcare Health Plans, Inc.
WCG
$26.9M 1.22%
134,000
-63,500
-32% -$12.3M
LOXO
24
DELISTED
Loxo Oncology, Inc
LOXO
$26.1M 1.18%
310,000
+24,500
+9% +$2.04M
ONC
25
BeOne Medicines Ltd
ONC
$33.9B
$26M 1.18%
266,000
-14,000
-5% -$1.28M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Rock Springs Capital Management held 159 positions worth $2.2B, up 1.7% from $2.17B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management's Q4 2017 filing shows 12 new, 46 increased, 21 reduced and 14 closed positions. Its largest new stake was Teleflex: 91,750 shares worth $22.8M. The largest sale was Aetna Inc, an estimated $27.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 80% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2017 buy was Teleflex: 91,750 shares worth $22.8M.
  • Rock Springs Capital Management added most to Zimmer Biomet in Q4 2017, an estimated $11.4M increase.
  • Rock Springs Capital Management's biggest Q4 2017 reduction was Aetna Inc, cutting an estimated $27.5M.
  • Rock Springs Capital Management fully exited Danaher in Q4 2017, selling an estimated $19.3M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $2.2B portfolio in Q4 2017.
  • Rock Springs Capital Management opened 12 new positions and closed 14 in Q4 2017.
  • Rock Springs Capital Management's portfolio value rose 1.7% quarter-over-quarter to $2.2B.

Based on Rock Springs Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.